Form 4: KalVista CDO Reports RSU Vesting and Tax-Related Stock Sale

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, Inc. (KALV), reported transactions involving the company's common stock.
• On November 21, 2025, 3,750 Restricted Stock Units (RSUs) vested and settled, converting into 3,750 shares of Common Stock.
• On November 22, 2025, an additional 3,125 RSUs vested and settled, converting into 3,125 shares of Common Stock.
• On November 24, 2025, 4,331 shares of Common Stock were sold at a price of $13.451 per share.
• The sale of shares was a non-discretionary 'sell to cover' transaction, executed solely to satisfy tax withholding obligations associated with the RSU vesting.
• Following these reported transactions, Christopher Yea beneficially owns 223,508 shares of KalVista Pharmaceuticals, Inc. Common Stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation (RSU vesting and tax-related stock sale), which are neither inherently positive nor negative for the company's operational performance or future prospects.

Positives

• The sale of shares was explicitly stated as a non-discretionary transaction solely to cover tax withholding obligations related to RSU vesting, rather than a discretionary sale by the reporting person.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This insider transaction report is specific to an individual executive's compensation and does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• Christopher Yea, Chief Development Officer, received shares from the company through the vesting and settlement of Restricted Stock Units (RSUs) as part of his compensation plan.

Stakeholder Impact

• Shareholders may note the change in beneficial ownership by a key executive, but the non-discretionary nature of the sale for tax purposes suggests no change in management's confidence in the company.

Key Dates

Recommendation

The Form 4 filing details routine insider transactions involving the vesting of Restricted Stock Units and a subsequent 'sell to cover' sale to satisfy tax obligations. These non-discretionary transactions do not reflect a change in management's confidence or the company's operational performance, thus providing no new information to warrant a change from a 'hold' position based solely on this filing.

Keywords

KalVista Pharmaceuticals, KALV, Form 4, insider transaction, RSU vesting, stock sale, tax withholding, Chief Development Officer, Christopher Yea